Holen Sie sich die Stockscreener-App
4.20
1.20%
0.05
Schlusskurs vom Vortag:
$4.15
Offen:
$4.12
24-Stunden-Volumen:
167.47K
Relative Volume:
0.77
Marktkapitalisierung:
$183.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
+26.13%
6M Leistung:
-24.05%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.91
$4.44
1-Wochen-Bereich:
$3.91
$4.44
52-Wochen-Spanne:
$1.80
$7.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
Firmenname
Tuhura Biosciences Inc
Sektor
Branche
Telefon
813-875-6600
Adresse
10500 UNIVERSITY CENTER DR., TAMPA
Vergleichen Sie HURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
4.20 | 183.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-11-05 | Eingeleitet | Maxim Group | Buy |
Tuhura Biosciences Inc Aktie (HURA) Neueste Nachrichten
Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study - Quantisnow
Equities Analysts Offer Predictions for HURA Q3 Earnings - Defense World
HURA: 2024 Financial Results - Zacks Small Cap Research
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting - PR Newswire
TuHURA Biosciences hires new EVP for drug development By Investing.com - Investing.com South Africa
TuHURA Biosciences hires new EVP for drug development - Investing.com India
Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President - MarketScreener
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - PR Newswire
Q2 EPS Estimate for TuHURA Biosciences Increased by Analyst - Defense World
Q3 Earnings Estimate for HURA Issued By HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for TuHURA Biosciences (NASDAQ:HURA) Stock Price - Defense World
H.C. Wainwright cuts TuHURA Biosciences target to $12; Keeps Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts TuHURA Biosciences target to $12; Keeps Buy - Investing.com
Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans? - Yahoo
Charles Schwab Investment Management Inc. Purchases New Position in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 - TradingView
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - PR Newswire
TuHURA Biosciences (NASDAQ:HURA) Stock Price Up 1.7% – Still a Buy? - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
TuHURA Biosciences Announces Acquisition of Kineta, Inc. - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
TuHURA Biosciences Expands Board with New Appointment - TipRanks
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors - Joplin Globe
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference - Eagle-Tribune
What is HC Wainwright’s Estimate for HURA Q2 Earnings? - Defense World
KINETA, INC./DE SEC 10-K Report - TradingView
TuHURA Biosciences (NASDAQ:HURA) Now Covered by Analysts at HC Wainwright - Defense World
HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target -March 03, 2025 at 07:29 am EST - Marketscreener.com
TuHURA Biosciences (HURA) to Release Earnings on Wednesday - Defense World
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Milton Daily Standard
Press Release Distribution & PR Platform - ACCESS Newswire
Apollon Wealth Management LLC Invests $253,000 in TuHURA Biosciences (NASDAQ:HURA) - MarketBeat
TuHURA Biosciences: A Hold On Only The Faintest Glimmers Of Efficacy (NASDAQ:HURA) - Seeking Alpha
TuHURA Biosciences secures $3M through warrant exercises By Investing.com - Investing.com Australia
TuHURA Biosciences secures $3M through warrant exercises - Investing.com India
Finanzdaten der Tuhura Biosciences Inc-Aktie (HURA)
Es liegen keine Finanzdaten für Tuhura Biosciences Inc (HURA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):